Aytu Biopharma (AYTU) Depreciation & Amortization (CF) (2014 - 2024)

Aytu Biopharma (AYTU) has reported Depreciation & Amortization (CF) for 11 consecutive years, with $1.3 million the latest figure, recorded in Q4 2024.

• On a quarterly basis, Depreciation & Amortization (CF) fell 25.24% year-over-year to $1.3 million in Q4 2024; TTM through Sep 2025 was $1.3 million, a 82.96% decrease from a year earlier, with the FY2024 full-year figure at $8.3 million, down 6.16% from the prior year.
• Depreciation & Amortization (CF) was $1.3 million for Q4 2024 at Aytu Biopharma, down from $1.4 million in the prior quarter.
• Over five years, Depreciation & Amortization (CF) peaked at $3.3 million in Q2 2021 and troughed at $1.3 million in Q4 2024.
• A 5-year average of $2.2 million and a median of $2.2 million in 2023 frame the typical range for Depreciation & Amortization (CF).
• Across the five-year window, Depreciation & Amortization (CF) surged 156.85% in 2020 and tumbled 36.01% in 2024, its largest moves.
• Over 5 years, Depreciation & Amortization (CF) stood at $1.9 million in 2020, then jumped by 43.05% to $2.7 million in 2021, then decreased by 17.53% to $2.2 million in 2022, then retreated by 18.81% to $1.8 million in 2023, then slipped by 25.24% to $1.3 million in 2024.
• The last three Depreciation & Amortization (CF) figures came in at $1.3 million (Q4 2024), $1.4 million (Q3 2024), and $1.9 million (Q2 2024), per Business Quant data.